Aaldijk et al., 2023 - Google Patents

Biological and pharmacological functions of the FGF19-and FGF21-coreceptor beta klotho

Aaldijk et al., 2023

View HTML
Document ID
12030093207880915057
Author
Aaldijk A
Verzijl C
Jonker J
Struik D
Publication year
Publication venue
Frontiers in endocrinology

External Links

Snippet

Beta klotho (KLB) is a fundamental component in fibroblast growth factor receptor (FGFR) signaling as it serves as an obligatory coreceptor for the endocrine hormones fibroblast growth factor 19 (FGF19) and fibroblast growth factor 21 (FGF21). Through the development …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines

Similar Documents

Publication Publication Date Title
Aaldijk et al. Biological and pharmacological functions of the FGF19-and FGF21-coreceptor beta klotho
Henriksson et al. FGF19 and FGF21 for the treatment of NASH—two sides of the same coin? Differential and overlapping effects of FGF19 and FGF21 from mice to human
Maida et al. A liver stress-endocrine nexus promotes metabolic integrity during dietary protein dilution
Baumeier et al. Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease
Knorr et al. Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis
Tagi et al. Insulin resistance in children
Spann et al. The nuanced metabolic functions of endogenous FGF21 depend on the nature of the stimulus, tissue source, and experimental model
Huang et al. Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition
Mehran et al. Hyperinsulinemia drives diet-induced obesity independently of brain insulin production
Ozcan et al. Activation of calcium/calmodulin-dependent protein kinase II in obesity mediates suppression of hepatic insulin signaling
Tanigaki et al. C-reactive protein causes insulin resistance in mice through Fcγ receptor IIB–mediated inhibition of skeletal muscle glucose delivery
Bradley et al. Type 2 diabetes in the elderly: challenges in a unique patient population
Lei et al. Loss of CTRP5 improves insulin action and hepatic steatosis
US20120282184A1 (en) Treatment of obesity
Tsuchiya et al. Liver sinusoidal endothelial cells link hyperinsulinemia to hepatic insulin resistance
Ding et al. Nonalcoholic fatty liver disease
Dhounchak et al. Heparan sulfate proteoglycans in beta cells provide a critical link between endoplasmic reticulum stress, oxidative stress and type 2 diabetes
McGlone et al. Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence
Wang et al. Secreted EMC10 is upregulated in human obesity and its neutralizing antibody prevents diet-induced obesity in mice
Gelegen et al. Regulation of hindbrain Pyy expression by acute food deprivation, prolonged caloric restriction, and weight loss surgery in mice
Zhong et al. Genetic or pharmacologic blockade of mPGES-2 attenuates renal lipotoxicity and diabetic kidney disease by targeting Rev-Erbα/FABP5 signaling
Hwang et al. Exocytosis proteins: typical and atypical mechanisms of action in skeletal muscle
Yu et al. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice
Keller et al. What the BTBR/J mouse has taught us about diabetes and diabetic complications
AlSaraj Pathogenesis of type 2 diabetes mellitus